How alpha-synuclein affects tau protein and related dementia
Regulation of human tau expression and tauopathy by alpha-synuclein
This study is looking at how two proteins, alpha-synuclein and tau, work together in the brain and how they might affect memory and thinking in people with dementia, like Alzheimer's, to see if removing one of them can help improve brain function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11080340 on NIH RePORTER |
What this research studies
This research investigates the relationship between alpha-synuclein and tau proteins, which are both implicated in various forms of dementia, including Alzheimer's disease. Using advanced genetic techniques in mouse models, the study aims to understand how alpha-synuclein influences tau expression and pathology, potentially affecting cognitive functions. The researchers will explore whether removing the gene responsible for alpha-synuclein can reduce tau-related cognitive deficits, providing insights into new therapeutic strategies for dementia. This work could lead to a better understanding of the biological mechanisms behind these diseases and inform future treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those with mixed neuropathologies.
Not a fit: Patients with dementia not associated with tau or alpha-synuclein pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating dementia by targeting the interactions between alpha-synuclein and tau proteins.
How similar studies have performed: Other research has shown promising results in understanding the roles of alpha-synuclein and tau in dementia, suggesting that this approach could yield significant insights.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Lee, Michael K — University of Minnesota
- Study coordinator: Lee, Michael K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.